Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma
AbstractRenal cell carcinoma (RCC) is a heterogeneous disease that is usually asymptomatic until late in the disease. There is an urgent need for RCC specific biomarkers that may be exploited clinically for diagnostic and prognostic purposes. Preoperative fasting urine and serum samples were collected from patients with clinical renal masses and assessed with 1H NMR and GCMS (gas chromatography-mass spectrometry) based metabolomics and multivariate statistical analysis. Alterations in levels of glycolytic and tricarboxylic acid (TCA) cycle intermediates were detected in RCC relative to benign masses. Orthogonal Partial Least Square Discriminant Analysis plots discriminated between benign vs. pT1 (R2 = 0.46, Q2 = 0.28; AUC = 0.83), benign vs. pT3 (R2 = 0.58, Q2 = 0.37; AUC = 0.87) for 1H NMR-analyzed serum and between benign vs. pT1 (R2 = 0.50, Q2 = 0.37; AUC = 0.83), benign vs. pT3 (R2 = 0.72, Q2 = 0.68, AUC = 0.98) for urine samples. Separation was observed between benign vs. pT3 (R2 = 0.63, Q2 = 0.48; AUC = 0.93), pT1 vs. pT3 (R2 = 0.70, Q2 = 0.54) for GCMS-analyzed serum and between benign vs. pT3 (R2Y = 0.87; Q2 = 0.70; AUC = 0.98) for urine samples. This pilot study suggests that urine and serum metabolomics may be useful in differentiating benign renal tumors from RCC and for staging RCC. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 372 KB)
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Falegan, O.S.; Ball, M.W.; Shaykhutdinov, R.A.; Pieroraio, P.M.; Farshidfar, F.; Vogel, H.J.; Allaf, M.E.; Hyndman, M.E. Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma. Metabolites 2017, 7, 6.
Falegan OS, Ball MW, Shaykhutdinov RA, Pieroraio PM, Farshidfar F, Vogel HJ, Allaf ME, Hyndman ME. Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma. Metabolites. 2017; 7(1):6.Chicago/Turabian Style
Falegan, Oluyemi S.; Ball, Mark W.; Shaykhutdinov, Rustem A.; Pieroraio, Phillip M.; Farshidfar, Farshad; Vogel, Hans J.; Allaf, Mohamad E.; Hyndman, Matthew E. 2017. "Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma." Metabolites 7, no. 1: 6.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.